Market Overview:
The global gefitinib API market is expected to grow at a CAGR of XX% during the forecast period from 2018 to 2030. The growth in this market can be attributed to the increasing prevalence of cancer, rising demand for gefitinib API in tablets, and growing investments by pharmaceutical companies in R&D activities. However, the high cost of development and stringent regulatory requirements are some of the major factors restraining the growth of this market. Based on type, the global gefitinib API market is segmented into purity ≥ 98 % and purity ≥ 99 %. The purity ≥ 98 % segment is expected to account for a larger share of this market than the purity ≥ 99 % segment during the forecast period from 2018 to 2030. This can be attributed to its lower cost as compared with other types of gefitinib APIs and its wide adoption across various applications. Based on application, the global gefitinib API market is divided into tablets and other applications.
Product Definition:
Gefitinib API is a drug used to treat non-small cell lung cancer. It is a kinase inhibitor that works by blocking the action of enzymes that promote tumor growth.
Purity ≥ 98 %:
Purity more than 98% is considered as a high purity compound. High purity compounds are used in the pharmaceutical industry for various applications such as drug development, research, and quality control. Increasing R&D activities by many pharmaceutical companies has led to the growth of this market.
Increasing demand for advanced drugs with fewer side effects is also one of the major factors driving this market globally.
Purity ≥ 99 %:
Gefitinib is a drug used for the treatment of breast cancer. It works by blocking the growth of cancer cells in patients. The main ingredient in Gefitinib is everolimus which has anti-cancer properties and helps to stop tumor growth.
Application Insights:
The other application segment accounted for the largest revenue share of over 50.0% in 2017 and is expected to continue its dominance over the forecast period. The major applications include gefitinib tablets, gefitinib powder, and others such as gefitinib solvate (g-H2SO4), D-glufosinate (D-glucosamine sulfate) and L-carnitine fumarate. Other applications are expected to witness significant growth due to increasing product usage in cancer treatment along with rising R&D initiatives by key companies operating in the market space.
Growth of oncology therapeutics industry coupled with growing adoption of targeted therapy drugs is anticipated to drive demand for these products across various cancer indications during the forecast period.
Regional Analysis:
North America dominated the global gefitinib API market in 2017. This is attributed to the presence of key players, such as Pfizer Inc.; Merck & Co., Inc.; and Celgene Corporation. Moreover, these companies are engaged in extensive R&D activities for drug development to meet unmet medical needs and increase patient compliance rates.
Asia Pacific is expected to witness lucrative growth over the forecast period owing to increasing healthcare expenditure by governments and private sectors coupled with rising awareness about advanced treatment options for cancer patients in emerging economies including China, India, South Korea, Taiwan Province of China (China), Hong Kong (China) among others.
Growth Factors:
- Increasing incidence of lung cancer: The incidence of lung cancer is increasing at an alarming rate across the globe. This is primarily attributed to the rising levels of pollution and smoking habits. As a result, there is a growing demand for effective and safe treatment options for lung cancer, which is expected to drive the growth of the Gefitinib API market in the coming years.
- Rising awareness about Gefitinib: There is a growing awareness about Gefitinib as an effective treatment option for lung cancer among patients and healthcare professionals alike. This is likely to boost demand for Gefitinib API in the coming years.
- Growing investment in R&D activities: Pharmaceutical companies are investing heavily in R&D activities to develop novel therapies for various diseases, including lung cancer. This is expected to fuel growth of the Gefitinib API market in future years.
Scope Of The Report
Report Attributes
Report Details
Report Title
Gefitinib API Market Research Report
By Type
Purity ≥ 98 %, Purity ≥ 99 %
By Application
Gefitinib Tablets, Other
By Companies
Scion Pharm Taiwan, Farmhispania Group, Chem Genix, Jeil Pharmaceutical, Zhuhai Rundu Pharma, Cipla, Brawn Laboratories, Nischem International, Zhejiang Hisun Pharmaceutical, Qilu Pharmaceutial, Scion Pharm Taiwan
Regions Covered
North America, Europe, APAC, Latin America, MEA
Base Year
2021
Historical Year
2019 to 2020 (Data from 2010 can be provided as per availability)
Forecast Year
2030
Number of Pages
146
Number of Tables & Figures
103
Customization Available
Yes, the report can be customized as per your need.
Global Gefitinib API Market Report Segments:
The global Gefitinib API market is segmented on the basis of:
Types
Purity ≥ 98 %, Purity ≥ 99 %
The product segment provides information about the market share of each product and the respective CAGR during the forecast period. It lays out information about the product pricing parameters, trends, and profits that provides in-depth insights of the market. Furthermore, it discusses latest product developments & innovation in the market.
Applications
Gefitinib Tablets, Other
The application segment fragments various applications of the product and provides information on the market share and growth rate of each application segment. It discusses the potential future applications of the products and driving and restraining factors of each application segment.
Some of the companies that are profiled in this report are:
- Scion Pharm Taiwan
- Farmhispania Group
- Chem Genix
- Jeil Pharmaceutical
- Zhuhai Rundu Pharma
- Cipla
- Brawn Laboratories
- Nischem International
- Zhejiang Hisun Pharmaceutical
- Qilu Pharmaceutial
- Scion Pharm Taiwan
Highlights of The Gefitinib API Market Report:
- The market structure and projections for the coming years.
- Drivers, restraints, opportunities, and current trends of market.
- Historical data and forecast.
- Estimations for the forecast period 2030.
- Developments and trends in the market.
- By Type:
- Purity ≥ 98 %
- Purity ≥ 99 %
- By Application:
- Gefitinib Tablets
- Other
- Market scenario by region, sub-region, and country.
- Market share of the market players, company profiles, product specifications, SWOT analysis, and competitive landscape.
- Analysis regarding upstream raw materials, downstream demand, and current market dynamics.
- Government Policies, Macro & Micro economic factors are also included in the report.
We have studied the Gefitinib API Market in 360 degrees via. both primary & secondary research methodologies. This helped us in building an understanding of the current market dynamics, supply-demand gap, pricing trends, product preferences, consumer patterns & so on. The findings were further validated through primary research with industry experts & opinion leaders across countries. The data is further compiled & validated through various market estimation & data validation methodologies. Further, we also have our in-house data forecasting model to predict market growth up to 2030.
Regional Analysis
- North America
- Europe
- Asia Pacific
- Middle East & Africa
- Latin America
Note: A country of choice can be added in the report at no extra cost. If more than one country needs to be added, the research quote will vary accordingly.
The geographical analysis part of the report provides information about the product sales in terms of volume and revenue in regions. It lays out potential opportunities for the new entrants, emerging players, and major players in the region. The regional analysis is done after considering the socio-economic factors and government regulations of the countries in the regions.
How you may use our products:
- Correctly Positioning New Products
- Market Entry Strategies
- Business Expansion Strategies
- Consumer Insights
- Understanding Competition Scenario
- Product & Brand Management
- Channel & Customer Management
- Identifying Appropriate Advertising Appeals
8 Reasons to Buy This Report
- Includes a Chapter on the Impact of COVID-19 Pandemic On the Market
- Report Prepared After Conducting Interviews with Industry Experts & Top Designates of the Companies in the Market
- Implemented Robust Methodology to Prepare the Report
- Includes Graphs, Statistics, Flowcharts, and Infographics to Save Time
- Industry Growth Insights Provides 24/5 Assistance Regarding the Doubts in the Report
- Provides Information About the Top-winning Strategies Implemented by Industry Players.
- In-depth Insights On the Market Drivers, Restraints, Opportunities, and Threats
- Customization of the Report Available
Frequently Asked Questions?
The Gefitinib API is a set of programming interfaces that allow developers to access and manage data associated with gefitinib therapy. The APIs provide access to information such as drug concentrations, patient demographics, and clinical trial results.
Some of the major companies in the gefitinib api market are Scion Pharm Taiwan, Farmhispania Group, Chem Genix, Jeil Pharmaceutical, Zhuhai Rundu Pharma, Cipla, Brawn Laboratories, Nischem International, Zhejiang Hisun Pharmaceutical, Qilu Pharmaceutial, Scion Pharm Taiwan.
Chapter 1 Executive Summary
Chapter 2 Assumptions and Acronyms Used
Chapter 3 Research Methodology
Chapter 4 Gefitinib API Market Overview 4.1 Introduction 4.1.1 Market Taxonomy 4.1.2 Market Definition 4.1.3 Macro-Economic Factors Impacting the Market Growth 4.2 Gefitinib API Market Dynamics 4.2.1 Market Drivers 4.2.2 Market Restraints 4.2.3 Market Opportunity 4.3 Gefitinib API Market - Supply Chain Analysis 4.3.1 List of Key Suppliers 4.3.2 List of Key Distributors 4.3.3 List of Key Consumers 4.4 Key Forces Shaping the Gefitinib API Market 4.4.1 Bargaining Power of Suppliers 4.4.2 Bargaining Power of Buyers 4.4.3 Threat of Substitution 4.4.4 Threat of New Entrants 4.4.5 Competitive Rivalry 4.5 Global Gefitinib API Market Size & Forecast, 2018-2028 4.5.1 Gefitinib API Market Size and Y-o-Y Growth 4.5.2 Gefitinib API Market Absolute $ Opportunity
Chapter 5 Global Gefitinib API Market Analysis and Forecast by Type
5.1 Introduction
5.1.1 Key Market Trends & Growth Opportunities by Type
5.1.2 Basis Point Share (BPS) Analysis by Type
5.1.3 Absolute $ Opportunity Assessment by Type
5.2 Gefitinib API Market Size Forecast by Type
5.2.1 Purity ≥ 98 %
5.2.2 Purity ≥ 99 %
5.3 Market Attractiveness Analysis by Type
Chapter 6 Global Gefitinib API Market Analysis and Forecast by Applications
6.1 Introduction
6.1.1 Key Market Trends & Growth Opportunities by Applications
6.1.2 Basis Point Share (BPS) Analysis by Applications
6.1.3 Absolute $ Opportunity Assessment by Applications
6.2 Gefitinib API Market Size Forecast by Applications
6.2.1 Gefitinib Tablets
6.2.2 Other
6.3 Market Attractiveness Analysis by Applications
Chapter 7 Global Gefitinib API Market Analysis and Forecast by Region
7.1 Introduction
7.1.1 Key Market Trends & Growth Opportunities by Region
7.1.2 Basis Point Share (BPS) Analysis by Region
7.1.3 Absolute $ Opportunity Assessment by Region
7.2 Gefitinib API Market Size Forecast by Region
7.2.1 North America
7.2.2 Europe
7.2.3 Asia Pacific
7.2.4 Latin America
7.2.5 Middle East & Africa (MEA)
7.3 Market Attractiveness Analysis by Region
Chapter 8 Coronavirus Disease (COVID-19) Impact
8.1 Introduction
8.2 Current & Future Impact Analysis
8.3 Economic Impact Analysis
8.4 Government Policies
8.5 Investment Scenario
Chapter 9 North America Gefitinib API Analysis and Forecast
9.1 Introduction
9.2 North America Gefitinib API Market Size Forecast by Country
9.2.1 U.S.
9.2.2 Canada
9.3 Basis Point Share (BPS) Analysis by Country
9.4 Absolute $ Opportunity Assessment by Country
9.5 Market Attractiveness Analysis by Country
9.6 North America Gefitinib API Market Size Forecast by Type
9.6.1 Purity ≥ 98 %
9.6.2 Purity ≥ 99 %
9.7 Basis Point Share (BPS) Analysis by Type
9.8 Absolute $ Opportunity Assessment by Type
9.9 Market Attractiveness Analysis by Type
9.10 North America Gefitinib API Market Size Forecast by Applications
9.10.1 Gefitinib Tablets
9.10.2 Other
9.11 Basis Point Share (BPS) Analysis by Applications
9.12 Absolute $ Opportunity Assessment by Applications
9.13 Market Attractiveness Analysis by Applications
Chapter 10 Europe Gefitinib API Analysis and Forecast
10.1 Introduction
10.2 Europe Gefitinib API Market Size Forecast by Country
10.2.1 Germany
10.2.2 France
10.2.3 Italy
10.2.4 U.K.
10.2.5 Spain
10.2.6 Russia
10.2.7 Rest of Europe
10.3 Basis Point Share (BPS) Analysis by Country
10.4 Absolute $ Opportunity Assessment by Country
10.5 Market Attractiveness Analysis by Country
10.6 Europe Gefitinib API Market Size Forecast by Type
10.6.1 Purity ≥ 98 %
10.6.2 Purity ≥ 99 %
10.7 Basis Point Share (BPS) Analysis by Type
10.8 Absolute $ Opportunity Assessment by Type
10.9 Market Attractiveness Analysis by Type
10.10 Europe Gefitinib API Market Size Forecast by Applications
10.10.1 Gefitinib Tablets
10.10.2 Other
10.11 Basis Point Share (BPS) Analysis by Applications
10.12 Absolute $ Opportunity Assessment by Applications
10.13 Market Attractiveness Analysis by Applications
Chapter 11 Asia Pacific Gefitinib API Analysis and Forecast
11.1 Introduction
11.2 Asia Pacific Gefitinib API Market Size Forecast by Country
11.2.1 China
11.2.2 Japan
11.2.3 South Korea
11.2.4 India
11.2.5 Australia
11.2.6 South East Asia (SEA)
11.2.7 Rest of Asia Pacific (APAC)
11.3 Basis Point Share (BPS) Analysis by Country
11.4 Absolute $ Opportunity Assessment by Country
11.5 Market Attractiveness Analysis by Country
11.6 Asia Pacific Gefitinib API Market Size Forecast by Type
11.6.1 Purity ≥ 98 %
11.6.2 Purity ≥ 99 %
11.7 Basis Point Share (BPS) Analysis by Type
11.8 Absolute $ Opportunity Assessment by Type
11.9 Market Attractiveness Analysis by Type
11.10 Asia Pacific Gefitinib API Market Size Forecast by Applications
11.10.1 Gefitinib Tablets
11.10.2 Other
11.11 Basis Point Share (BPS) Analysis by Applications
11.12 Absolute $ Opportunity Assessment by Applications
11.13 Market Attractiveness Analysis by Applications
Chapter 12 Latin America Gefitinib API Analysis and Forecast
12.1 Introduction
12.2 Latin America Gefitinib API Market Size Forecast by Country
12.2.1 Brazil
12.2.2 Mexico
12.2.3 Rest of Latin America (LATAM)
12.3 Basis Point Share (BPS) Analysis by Country
12.4 Absolute $ Opportunity Assessment by Country
12.5 Market Attractiveness Analysis by Country
12.6 Latin America Gefitinib API Market Size Forecast by Type
12.6.1 Purity ≥ 98 %
12.6.2 Purity ≥ 99 %
12.7 Basis Point Share (BPS) Analysis by Type
12.8 Absolute $ Opportunity Assessment by Type
12.9 Market Attractiveness Analysis by Type
12.10 Latin America Gefitinib API Market Size Forecast by Applications
12.10.1 Gefitinib Tablets
12.10.2 Other
12.11 Basis Point Share (BPS) Analysis by Applications
12.12 Absolute $ Opportunity Assessment by Applications
12.13 Market Attractiveness Analysis by Applications
Chapter 13 Middle East & Africa (MEA) Gefitinib API Analysis and Forecast
13.1 Introduction
13.2 Middle East & Africa (MEA) Gefitinib API Market Size Forecast by Country
13.2.1 Saudi Arabia
13.2.2 South Africa
13.2.3 UAE
13.2.4 Rest of Middle East & Africa (MEA)
13.3 Basis Point Share (BPS) Analysis by Country
13.4 Absolute $ Opportunity Assessment by Country
13.5 Market Attractiveness Analysis by Country
13.6 Middle East & Africa (MEA) Gefitinib API Market Size Forecast by Type
13.6.1 Purity ≥ 98 %
13.6.2 Purity ≥ 99 %
13.7 Basis Point Share (BPS) Analysis by Type
13.8 Absolute $ Opportunity Assessment by Type
13.9 Market Attractiveness Analysis by Type
13.10 Middle East & Africa (MEA) Gefitinib API Market Size Forecast by Applications
13.10.1 Gefitinib Tablets
13.10.2 Other
13.11 Basis Point Share (BPS) Analysis by Applications
13.12 Absolute $ Opportunity Assessment by Applications
13.13 Market Attractiveness Analysis by Applications
Chapter 14 Competition Landscape
14.1 Gefitinib API Market: Competitive Dashboard
14.2 Global Gefitinib API Market: Market Share Analysis, 2019
14.3 Company Profiles (Details – Overview, Financials, Developments, Strategy)
14.3.1 Scion Pharm Taiwan
14.3.2 Farmhispania Group
14.3.3 Chem Genix
14.3.4 Jeil Pharmaceutical
14.3.5 Zhuhai Rundu Pharma
14.3.6 Cipla
14.3.7 Brawn Laboratories
14.3.8 Nischem International
14.3.9 Zhejiang Hisun Pharmaceutical
14.3.10 Qilu Pharmaceutial
14.3.11 Scion Pharm Taiwan